Management of menorrhagia associated with chemotherapy-induced thrombocytopenia in women with hematologic malignancy

Pharmacotherapy

Volumn 31, Issue 11, 2011, Pages 1092-1110

  Bates, Jill S ^a   Buie, Larry W ^a   Woodis, C Brock ^b  

^a UNIVERSITY OF NORTH CAROLINA HOSPITALS   (United States)

^b CAMPBELL UNIVERSITY   (United States)

Author keywords

Chemotherapy; Leuprolide; Menorrhagia; Menses; Pharmacotherapy; Thrombocytopenia; Tranexamic acid

Indexed keywords

AMINOCAPROIC ACID; CONJUGATED ESTROGEN; DANAZOL; DESMOPRESSIN; DROSPIRENONE PLUS ETHINYLESTRADIOL; ESTROGEN; ETHINYLESTRADIOL PLUS GESTODENE; GESTAGEN; GONADORELIN AGONIST; GONADORELIN DERIVATIVE; HYDROXYCHLOROQUINE; IBUPROFEN; INDOMETACIN; LEUPRORELIN; LEVONORGESTREL; MEDROXYPROGESTERONE; MEDROXYPROGESTERONE ACETATE; MEFENAMIC ACID; NAPROXEN; NOMEGESTROL ACETATE; NONSTEROID ANTIINFLAMMATORY AGENT; ORAL CONTRACEPTIVE AGENT; PLACEBO; RECOMBINANT BLOOD CLOTTING FACTOR 7A; TRANEXAMIC ACID; TRIPTORELIN;

ABDOMINAL CRAMP; ABDOMINAL DISCOMFORT; ABSCESS; ACNE; ADD ON THERAPY; ADVERSE OUTCOME; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOATING; BLOOD DYSCRASIA; BONE DENSITY; BRAIN ISCHEMIA; BREAKTHROUGH BLEEDING; BREAST; BREAST TENDERNESS; CANCER CHEMOTHERAPY; CANCER PATIENT; COLOR VISION DEFECT; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG MEGADOSE; DRUG WITHDRAWAL; DYSMENORRHEA; EDEMA; ERYTHEMA; FATIGUE; FOOD; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; GRANULOMA; HEADACHE; HEART MUSCLE ISCHEMIA; HEMATOLOGIC MALIGNANCY; HEMATOMA; HIRSUTISM; HORMONAL THERAPY; HOT FLUSH; HUMAN; HYPERTENSION; INJECTION SITE PAIN; INJECTION SITE ULCER; LEG PAIN; LEUKEMIA; LIPID BLOOD LEVEL; LIVER TOXICITY; MENORRHAGIA; METRORRHAGIA; MUSCLE CRAMP; MYALGIA; NAUSEA; NIGHT SWEAT; PREMENOPAUSE; QUALITY OF LIFE; RECOMMENDED DRUG DOSE; REVIEW; SIDE EFFECT; SUBCUTANEOUS NODULE; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; THROMBOGENESIS; TREATMENT INDICATION; URTICARIA; VAGINA BLEEDING; VAGINITIS; VENOUS THROMBOEMBOLISM; VOMITING; WEIGHT GAIN;

ANIMALS; ANTIFIBRINOLYTIC AGENTS; ANTINEOPLASTIC AGENTS; FEMALE; HEMATOLOGIC NEOPLASMS; HUMANS; MENORRHAGIA; QUALITY OF LIFE; THROMBOCYTOPENIA; TRANEXAMIC ACID;

EID: 80054925981     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.31.11.1092     Document Type: Review

References (74)

1. Casablanca Y. Management of dysfunctional uterine bleeding. Obstet Gynecol Clin North Am 2008;35:219-34. (Pubitemid 351671995)
2. Middleton LJ, Champaneria R, Daniels JP, et al. Hysterectomy, endometrial destruction, and levonorgestrel releasing intrauterine system (Mirena) for heavy menstrual bleeding: systematic review and meta-analysis of data from individual patients [online exclusive article]. BMJ 2010;341:c3929. Available from http://dx.doi.org/10.1136/ bmj.c3929.
3. Shankar M, Chi C, Kadir RA. Review of quality of life: menorrhagia in women with or without inherited bleeding disorders. Haemophilia 2008;14:15-20.
4. The ESHRE Capri Workshop Group. Endometrial bleeding. Hum Reprod Update 2007;13:421-31.
5. Nicholson WK, Ellison SA, Grason H, Powe NR. Patterns of ambulatory care use for gynecologic conditions: a national study. Am J Obstet Gynecol 2001;184:523-30. (Pubitemid 32234961)
6. Vilos GA, Lefebvre G, Graves GR. Guidelines for the management of abnormal uterine bleeding. J Obstet Gynaecol Can 2001;23:704-9.
7. Telner DE, Jakubovicz D. Approach to diagnosis and management of abnormal uterine bleeding. Can Fam Physician 2007;53:58-64. (Pubitemid 46166587)
8. Albers JR, Hull SK, Wesley RM. Abnormal uterine bleeding. Am Fam Physician 2004;69:1915-26.
9. Ely JW, Kennedy CM, Clark EC, Bowdler NC. Abnormal uterine bleeding: a management algorithm. J Am Board Fam Med 2006;19:590-602. (Pubitemid 44736814)
10. Apgar BS, Kaufman AH, George-Nwogu U, Kittendorf A. Treatment of menorrhagia. Am Fam Physician 2007;75:1813-20.
11. Livingstone MK, Fraser IS. Mechanisms of abnormal uterine bleeding. Hum Reprod Update 2002;8:60-7. (Pubitemid 34144986)
12. Lukes AS, Reardon B, Arepally G. Use of the levonorgestrel intrauterine system in women with hemostatic disorders. Fertil Steril 2008;90:673-7.
13. Woolcock JG, Critchley HOD, Munro MG, Broder MS, Fraser IS. Review of the confusion in current and historical terminology and definitions for disturbances of menstrual bleeding. Fertil Steril 2008;90:2269-80.
14. Farage MA, Neill S, MacLean AB. Physiological changes associated with the menstrual cycle. Obstet Gynecol Surv 2009:64:58-72.
15. Mitchell SC, Smith RL, Waring RH. The menstrual cycle and drug metabolism. Curr Drug Metab 2009;10:499-507.
16. Christian CA, Moenter SM. The neurobiology of preovulatory and estradiol-induced gonadotropin-releasing hormone surges. Endocr Rev 2010;31:544-77.
17. Tsutsumi R, Webster NJG. GnRH pulsatility, the pituitary response and reproductive dysfunction. Endocr J 2009;56:729-37.
18. Roy SN, Bhattacharya S. Benefits and risks of pharmacological agents used for the treatment of menorrhagia. Drug Saf 2004;27:75-90. (Pubitemid 38186951)
19. Marret H, Fauconnier A, Chabbert-Buffet N, et al. Clinical practice guidelines on menorrhagia: management of abnormal uterine bleeding before menopause. Eur J Obstet Gynecol Reprod Biol 2010;152:133-7.
20. Bushnell DM, Martin ML, Moore KA, Richter HE, Rubin A, Patrick DL. Menorrhagia impact questionnaire: assessing the influence of heavy menstrual bleeding on quality of life. Curr Med Res Opin 2010;26:2745-55.
21. Lukes AS, Muse K, Richter HE, Moore KA, Patrick DL. Estimating a meaningful reduction in menstrual blood loss for women with heavy menstrual bleeding. Curr Med Res Opin 2010;26:2673-8.
22. Sanders JE, Buckner D, Amos D, et al. Ovarian function following marrow transplantation for aplastic anemia or leukemia. J Clin Oncol 1988;6:813-18.
23. Rivkees SA, Crawford JD. The relationship of gonadal activity and chemotherapy-induced gonadal damage. JAMA 1988;259:2123-5. (Pubitemid 18088500)
24. Bines J, Oleske DM, Cobleigh MA. Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. J Clin Oncol 1996;14:1718-29. (Pubitemid 26134232)
25. Meirow D. Ovarian injury and modern options to preserve fertility in female cancer patients treated with high dose radiochemotherapy for hemato-oncological neoplasias and other cancers. Leuk Lymphoma 1999;33:65-76. (Pubitemid 29116395)
26. Ferring Pharmaceuticals, Inc. Lysteda (tranexamic acid) package insert. Parsippany, NJ; 2010.
27. Bayer HealthCare Pharmaceuticals, Inc. Mirena (levonorgestrel-releasing intrauterine system) package insert. Wayne, NJ; 2009.
28. Martin-Johnston MK, Okojii OY, Armstrong A. Therapeutic amenorrhea in patients at risk for thrombocytopenia. Obstet Gynecol Surv 2008;63:395-402.
29. Amsterdam A, Jakubowski A, Castro-Malaspina H, et al. Treatment of menorrhagia in women undergoing hematopoietic stem cell transplantation. Bone Marrow Transplant 2004;34:363-6. (Pubitemid 39172445)
30. Levens ED, Scheinberg P, DeCherney AH. Severe menorrhagia associated with thrombocytopenia. Obstet Gynecol 2007;110:913-17. (Pubitemid 47508759)
31. Sica S, Salutari P, DiMario A, et al. Treatment and prophylaxis of hypermenorrhea with leuprorelin in premenopausal women affected by acute leukemia at diagnosis. Am J Hematol 1996;51:248-9. (Pubitemid 26089779)
32. Lhomme C, Brault PH, Bourhis JH, et al. Prevention of menstruation with leuprorelin (GnRH agonist) in women undergoing myelosuppressive chemotherapy or radiotherapy for hematological malignancies: a pilot study. Leuk Lymph 2001;42:1033-41. (Pubitemid 32827525)
33. Chiusolo P, Salutari P, Sica S, et al. Luteinizing hormone-releasing hormone analogue: leuprorelin acetate for the prevention of menstrual bleeding in premenopausal women undergoing stem cell transplantation. Bone Marrow Transplant 1998;21:821-3. (Pubitemid 28190627)
34. Laufer MR, Townsend NL, Parsons KE, et al. Inducing amenorrhea during bone marrow transplantation: a pilot study of leuprolide acetate. J Reprod Med 1997;42:537-41. (Pubitemid 27400979)
35. Meirow D, Rabinovici J, Katz D, Or R, Ben-Yehuda D. Prevention of severe menorrhagia in oncology patients with treatment-induced thrombocytopenia by luteinizing hormone-releasing hormone agonist and depo-medroxyprogesterone acetate. Cancer 2006;107:1634-41. (Pubitemid 44546925)
36. Ghalie R, Porter C, Radwanska E, Fitzsimmons W, Richman C, Kaizer H. Prevention of hypermenorrhea with leuprolide in premenopausal women undergoing bone marrow transplantation. Am J Hematol 1993;42:350-3. (Pubitemid 23104805)
37. Periti P, Mazzei T, Mini E. Clinical pharmacokinetics of depot leuprorelin. Clin Pharmacokinet 2002;41:485-504. (Pubitemid 34804161)
38. Sweetman S, ed. Martindale: the complete drug reference. Thomson Reuters. Available from http://www.thomsonhc.com/home/dispatch. Accessed February 21, 2011.
39. Abbott. Lupron (leuprolide acetate) package insert. North Chicago, IL; 2010.
40. Tolmar, Inc. Eligard (leuprolide acetate) package insert. Fort Collins, CO; 2010.
41. Akaza H, Aso Y, Koiso K, et al., for the TAP-144-SR Study Group. Leuprorelin acetate depot: results of a multicentre Japanese trial. J Int Med Res 1990;18(suppl 1):90-102. (Pubitemid 20052153)
42. Gerhard I, Schindler AE, Buhler K, et al. Treatment of endometriosis with leuprorelin acetate depot: a German multicentre study. Clin Ther 1992;14(suppl A):3-16.
43. Tanaka T. Long-term personalized GnRH agonist therapy without estrogen supplementation for recurrent endometriotic catamenial pneumothorax: case report. Clin Exp Obstet Gynecol 2007;34:179-81. (Pubitemid 47529249)
44. Chia CC, Huang SC, Chen SS, et al. Ultrasonographic evaluation of the change in uterine fibroids induced by treatment with a GnRH analog. Taiwanese J Obstet Gynecol 2006;45:124-8.
45. Lim SS, Sockaglingam JK, Tan PC. Goserelin versus leuprolide before hysterectomy for uterine fibroids. Int J Gynecol Obstet 2008;101:178-83.
46. Carel JC, Lahlou N, Jaramillo O, et al., for the French Leuprorelin Trial Group. Treatment of central precocious puberty with depot leuprorelin. Eur J Endocrinol 1995;132:699-704.
47. Schroeter M, Baus I, Sippell WG, Partsch CJ. Long-term suppression of pituitary-gonadal function with three month depot of leuprorelin acetate in a girl with central precocious puberty. Horm Res 2002;58:292-6. (Pubitemid 35404242)
48. Dangle P, Palit V, Sundaram SK, Weston P. Noninfective cutaneous granuloma with leuprorelin acetate - reality of myth. Urology 2007;69:779.e6.
49. Watanabe T, Yamada N, Yoshida Y, Yamamoto O. A morphological study of granulomas induced by subcutaneous injection of leuprorelin acetate. J Cutan Pathol 2009;36:1299-302.
50. Anderson FD, Hait H. A multicenter, randomized study of an extended cycle oral contraceptive. Contraception 2003;68:89-96. (Pubitemid 37101032)
51. The ESHRE Capri Workshop Group. Noncontraceptive health benefits of combined oral contraception. Hum Reprod Update 2005;11:513-25.
52. Burkman R, Schlesselman JJ, Zieman M. Safety concerns and health benefits associated with oral contraception. Am J Ob Gyn 2004;190:S5-22.
53. Oriel K, Schrager S. Abnormal uterine bleeding. Am Fam Physician 1999;60:1371-82. (Pubitemid 29498204)
54. Schaffner F. The effect of oral contraceptives on the liver. JAMA 1966;198:155-7.
55. Hagglund H, Remberger M, Klaesson S, Lonnqvist B, Ljungman P, Ringden O. Norethisterone treatment, a major risk factor for veno-occlusive disease in the liver after allogeneic bone marrow transplantation. Blood 1998;92:4568-72. (Pubitemid 29005858)
56. Nerayanan KV, Shah V, Kamath P. The Budd-Chiari syndrome. N Engl J Med 2004;350:578-85.
57. Schafer A. Effects of nonsteroidal anti-inflammatory drugs on platelet function and systemic hemostasis. J Clin Pharmacol 1995;35:209-19.
58. Slichter SJ. Relationship between platelet count and bleeding risk in thrombocytopenic patients. Transfus Med Rev 2004;18:153-67. (Pubitemid 38962484)
59. Lukes AS, Moore KA, Muse KN, et al. Tranexamic acid treatment for heavy menstrual bleeding. Obstet Gynecol 2010;116:865-75.
60. Sundstöm A, Seaman H, Kieler H, Alfredsson L. The risk of venous thromboembolism associated with the use of tranexamic acid and other drugs used to treat menorrhagia: a case-control study using the general practice research database. BJOG 2009;116:91-7.
61. Moore KA, Morin I, Marenco T, Lavigne JR, Morelli G. Pharmacokinetic studies in women of 2 novel oral formulations of tranexamic acid therapy for heavy menstrual bleeding [published online ahead of print January 18, 2011]. Am J Ther 2011. Available from http://dx.doi.org/10.1097/MJT.0b013e318205427a.
62. Moore KA, Callahan TS, Maison-blanche P, et al. Thorough cardiac QTc interval conductance assessment of a novel oral tranexamic acid treatment for heavy menstrual bleeding. Expert Opin Pharmacother 2010;11:2281-90.
63. Lethaby A, Irvine GA, Cameron IT. Cyclical progestogens for heavy menstrual bleeding. Cochrane Database Syst Rev 2008;(1)CD001016.
64. Vlieg AH, Helmerhorst FM, Vandenbrouke JP, et al. The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case-control study. BMJ 2009;339:h2921.
65. Chimbira TH, Anderson AB, Naish C, Cope E, Turnbull AC. Reduction of menstrual blood loss by danazol in unexplained menorrhagia: lak of effect of placebo. Br J Obstet Gynaecol 1980;87:1152-8. (Pubitemid 11199041)
66. Dockeray CJ, Sheppard BL, Bonnar J. Comparison between mefenamic acid and danazol in the treatment of established menorrhagia. Br J Obstet Ganeacol 1989;96:840-4. (Pubitemid 19186641)
67. Higham JM, Shaw RW. A comparative study of danazol, a regimen of decreasing doses of danazol, and norethindrone in the treatment of objectively proven unexplained menorrhagia. Am J Obstet Gynecol 1993;169:1134-9. (Pubitemid 24001627)
68. Guerriero S, Paoletti AM, Ajossa S, et al. Influence of vaginal danazol on uterine and brain perfusion during hormonal replacement therapy. Menopause 2001;8:424-8. (Pubitemid 33111578)
69. Telimaa S, Apter D, Reinila M, Ronnberg L, Kauppila A. A placebo-controlled comparison of hormonal and biochemical effects of danazol and high-dose medroxyprogesterone acetate. Eur J Obstet Gynaecol Reprod Biol 1990;36:97-105. (Pubitemid 20162065)
70. Ledford MR, Horton A, Wang G, Brito G, Delgado L. Efficacy of danazol in a patient with congenital protein-S deficiency: paradoxical evidence for decreased platelet activation and increased thrombin generation. Thromb Res 1997;87:473-82. (Pubitemid 27431630)
71. Luisi S, Razzi S, Lazzeri L, Bocchi C, Severi F, Petraglia F. Efficacy of vaginal danazol treatment in women with menorrhagia during fertile age. Fertil Steril 2009;92:1351-4.
72. Franchini M, Lippi G, Franchi M. The use of recombinant activated factor VII in obstetric and gynaecological haemorrhage. BJOG 2007;114:8-15. (Pubitemid 44923926)
73. Balci YI, Karabulut A, Kabukcu S, Sari I, Keski A. Intensive menstrual bleeding successfully treated with recombinant factor VIIa in Glanzmann thrombasthenia [published online ahead of print May 11, 2010]. Clin Appl Throb Hemost 2010 Available from http://cat.sagepub.com/content/early/2010/03/22/ 1076029610364518.long.
74. Eunice Kennedy Shriver National Institute of Child Health and Human Development. Treatment of menorrhagia in women with thrombocytopenia: comparison of platelet transfusion alone to platelet transfusion with continuous oral contraceptive pills. ClinicalTrials.gov. Bethesda, MD: National Library of Medicine. Available from http://clinicaltrials.gov/ct2/show/NCT00556400. Accessed February 24, 2011.